Tian MX, et al. - Through 28 immunohistochemically examined immune features of 352 hepatocellular carcinoma (HCC) specimens, the researchers intended to determine the postoperative survival for patients diagnosed with early/intermediate HCC by hypothetically assuming an improvement in the survival prediction by a novel tissue-related immune signature. An immune and clinical prognostic index, known as immune-clinical prognostic index (ICPI), was developed and validated in an independent dataset. Improvement and accuracy of survival prediction for patients with early/intermediate-stage HCC via ICPI, a useful and reliable prognostic tool were noted.